Bone metastases in gastric cancer follow a RANKL-independent mechanism

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1453-1458

  D'amico, Lucia ^a   Satolli, Maria Antonietta ^a   Mecca, Caterina ^a   Castiglione, Anna ^a   Ceccarelli, Manuela ^a   D'amelio, Patrizia ^b   Garino, Mauro ^b   De Giuli, Maurizio ^b   Sandrucci, Sergio ^c   Ferracini, Riccardo ^a   Roato, Ilaria ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Departments of Oncologic Surgery   (Italy)

Author keywords

Bone metastasis; Gastric cancer; Osteoclast; RANKL

Indexed keywords

DICKKOPF 1 PROTEIN; INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE CULTURE; MALE; OSTEOCLASTOGENESIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER;

AGED; BONE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-7; LEUKOCYTES, MONONUCLEAR; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; STOMACH NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874682891     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2280     Document Type: Article

References (41)

1. Sasako M, Inoue M, Lin JT, Khor C, Yang HK and Ohtsu A: Gastric Cancer Working Group Report. Jpn J Clin Oncol 40 (Suppl 1): i28-i37, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20, 2006.
4. AIRTUM Working Group: Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35 (5-6 Suppl 3): 1-200, 2011 (In Italian).
5. Amadori D, Cascinu S, Conte PF and Ibrahim T: Bone metas¬tases. In: Osteo-Oncology Textbook. Poletto Editore, Grafiche Cisalpina, S. Giuliano Milanese, pp200-201, 2010.
6. Kim HS, Yi SY, Jun HJ, et al: Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 73: 192-197, 2007.
7. Kobayashi M, Okabayashi T, Sano T and Araki K: Metastatic bone cancer as a recurrence of early gastric cancer-charac-teristics and possible mechanisms. World J Gastroenterol 11: 5587-5591, 2005.
8. Batson OV: The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res (312): 4-9, 1995.
9. Devkaran B, Jhobta R and Verma DK: Bony metastasis of gastric adenocarcinoma. Saudi J Gastroenterol 15: 137-138, 2009.
10. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
11. Hofbauer LC, Neubauer A and Heufelder AE: Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92: 460-470, 2001.
12. Kobayashi K, Takahashi N, Jimi E, et al: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism inde¬pendent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286, 2000.
13. Walsh MC and Choi Y: Biology of the TRANCE axis. Cytokine Growth Factor Rev 14: 251-263, 2003.
14. McGonigle JS, Giachelli CM and Scatena M: Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 12: 35-46, 2009.
15. Sfiridaki K, Pappa CA, Tsirakis G, et al: Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. Mediators Inflamm 2011: 867576, 2011.
16. Min JK, Cho YL, Choi JH, et al: Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 109: 1495-1502, 2007.
17. Carlevaro MF, Cermelli S, Cancedda R and Descalzi Cancedda F: Vascular endothelial growth factor (VEGF) in cartilage neovas¬cularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci 113: 59-69, 2000.
18. Vidal O, Metges JP, Elizalde I, et al: High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 96: 1443-1451, 2009.
19. Roato I, Grano M, Brunetti G, et al: Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 19: 228-230, 2005.
20. Brianza S, D'Amelio P, Cerrato M, Bignardi C, Grimaldi A, Pescarmona G and Isaia G: A dedicated image analysis software tool for the evaluation of the resorption activity of cultured osteo¬clasts. JIST 52: 30508-1-30508-9, 2008.
21. Roato I, D'Amelio P, Gorassini E, et al: Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 3: e3627, 2008.
22. D'Amelio P, Roato I, D'Amico L, et al: Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int 22: 2869-2877, 2011.
23. Roato I, Brunetti G, Gorassini E, et al: IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One 1: e124, 2006.
24. Roato I, Gorassini E, Buffoni L, et al: Spontaneous osteoclasto¬ genesis is a predictive factor for bone metastases from non-small cell lung cancer. Lung Cancer 61: 109-116, 2008.
25. Colucci S, Brunetti G, Rizzi R, et al: T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730, 2004.
26. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y and Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7, 2003.
27. Howlett M, Chalinor HV, Buzzelli JN, et al: IL-11 is a parietal cell cytokine that induces atrophic gastritis. Gut 61: 1398-1409, 2012.
28. Necula LG, Chivu-Economescu M, Stanciulescu EL, et al: IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis 21: 23-29, 2012.
29. Schinke T, Schilling AF, Baranowsky A, et al: Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 15: 674-681, 2009.
30. Juarez P and Guise TA: TGF-ß in cancer and bone: implications for treatment of bone metastases. Bone 48: 23-29, 2011.
31. Maehara Y, Kakeji Y, Kabashima A, et al: Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 17: 607-614, 1999.
32. Holen I and Shipman CM: Role of osteoprotegerin (OPG) in cancer. Clin Sci 110: 279-291, 2006.
33. Ito R, Nakayama H, Yoshida K, et al: Expression of osteopro¬tegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 443: 146-151, 2003.
34. Macsai CE, Foster BK and Xian CJ: Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol 215: 578-587, 2008.
35. Glass DA II, Bialek P, Ahn JD, et al: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764, 2005.
36. Morvan F, Boulukos K, Clement-Lacroix P, et al: Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945, 2006.
37. Tian E, Zhan F, Walker R, et al: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003.
38. Li ZG, Yang J, Vazquez ES, et al: Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27: 596-603, 2008.
39. Voorzanger-Rousselot N, Goehrig D, Journe F, et al: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97: 964-970, 2007.
40. Poon RT, Fan ST and Wong J: Clinical implications of circu¬lating angiogenic factors in cancer patients. J Clin Oncol 19: 1207-1225, 2001.
41. Fondevila C, Metges JP, Fuster J, et al: p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90: 206-215, 2004.